For the year ending 2025-12-31, MYGN had $39,400K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -365,900 |
| Depreciation and amortization | 53,700 |
| Non-cash lease expense | 7,700 |
| Stock-based compensation expense | 35,200 |
| Deferred income taxes | 100 |
| Unrecognized tax benefits | 32,500 |
| Impairment of goodwill and long-lived assets | 319,400 |
| (gain) loss on termination of lease | 0 |
| Gain on acquisition | 0 |
| Other non-cash adjustments | 3,400 |
| Prepaid expenses and other current assets | -200 |
| Trade accounts receivable | -6,200 |
| Inventory | 3,200 |
| Prepaid taxes | -4,400 |
| Other assets | -2,000 |
| Tenant improvement allowance received | 0 |
| Accounts payable | -1,400 |
| Accrued liabilities | -27,500 |
| Net cash provided by (used in) operating activities | 1,800 |
| Capital expenditures | 15,600 |
| Capitalization of intangible assets | 11,800 |
| Proceeds from the sale of business, net cash sold | 0 |
| Proceeds from maturities and sales of marketable investment securities | 0 |
| Net cash (used in) provided by investing activities | -27,400 |
| Proceeds from common stock issued under stock-based compensation plans | 3,300 |
| Payment of tax withheld for common stock issued under stock-based compensation plans | 7,300 |
| Proceeds from underwritten public offering, net of costs and discounts | 0 |
| Proceeds from revolving credit facility | 40,000 |
| Repayment of revolving credit facility | 80,500 |
| Proceeds from the issuance of secured long-term credit facility | 125,000 |
| Fees associated with issuance of secured long-term credit facility and refinancing of revolving credit facility-Secured Debt | 8,600 |
| Fees associated with issuance of secured long-term credit facility and refinancing of revolving credit facility-Revolving Credit Facility | 0 |
| Release of cash held in escrow | 7,500 |
| Other financing activities | -200 |
| Net cash provided by (used in) financing activities | 64,200 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | 800 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 39,400 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 111,900 |
| Cash, cash equivalents, and restricted cash at end of the period | 151,300 |
MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN)